Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Snapshot: Global Insulin Pumps Market Eyes Nearly 10% Growth By 2022

Executive Summary

The worldwide insulin pumps market is expected to reach more than $4.5bn by 2022, a CAGR of nearly 10%. This market is largely driven by the rising prevalence of diabetes and the need to control spiraling health-care costs associated with diabetes-related complications. While Medtronic's MiniMed 670G dominates the market, Informa's MedDeviceTracker expects Medtronic will see rising competition from innovative start-ups.

You may also be interested in...



Market Intel: CGM Market Competition And Device Interoperability Were Hot Topics At ADA2019

Interoperability and the rising use of continuous glucose monitoring is fueling competition among diabetes device-makers and dominated the conversation at the recent annual ADA meeting.

ADA Exec Chat: Hiten Chawla, Medtronic's VP Of Global Marketing Discusses Diabetes Business Plans

At this year's American Diabetes Association (ADA) meeting in San Francisco, medtech giant Medtronic made several key announcements including a collaboration with Tidepool Loop, the start of a new patient trial to develop its next-generation hybrid closed-loop system and another trial to improve its sensor technology. Medtech Insight met up with Hiten Chawla, Medtronic's VP of global marketing for its diabetes business, to learn more about these plans.

Grail’s Liquid Biopsy Can Detect Numerous Deadly Cancer Types Early

Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.

Topics

UsernamePublicRestriction

Register

MT124592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel